Growth Metrics

PAVmed (PAVM) Income towards Parent Company (2016 - 2025)

PAVmed has reported Income towards Parent Company over the past 5 years, most recently at -$2.8 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 341.42% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached -$2.5 million, up 92.35%, while the annual FY2025 figure was -$2.5 million, 108.69% down from the prior year.
  • Income towards Parent Company for Q4 2025 was -$2.8 million at PAVmed, up from -$6.0 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $18.6 million in Q1 2025 and troughed at -$29.9 million in Q3 2022.
  • A 5-year average of -$14.4 million and a median of -$17.4 million in 2023 define the central range for Income towards Parent Company.
  • On a YoY basis, Income towards Parent Company climbed as much as 200.6% in 2025 and fell as far as 341.42% in 2025.
  • Year by year, Income towards Parent Company stood at -$19.7 million in 2021, then dropped by 24.86% to -$24.6 million in 2022, then increased by 29.16% to -$17.4 million in 2023, then skyrocketed by 106.56% to $1.1 million in 2024, then tumbled by 341.42% to -$2.8 million in 2025.
  • Business Quant data shows Income towards Parent Company for PAVM at -$2.8 million in Q4 2025, -$6.0 million in Q3 2025, and -$12.3 million in Q2 2025.